PCSK9抑制剂在血脂管理中的临床研究与应用进展

Progress of clinical research and application of PCSK9 inhibitors on the management of dyslipidaemias

加强动脉粥样硬化性心血管疾病(ASCVD)患者的血脂管理,是延缓其疾病进展并改善远期预后的重要举措。然而,目前我国ASCVD患者血脂管理形势不容乐观,仍有较高比例的患者在接受传统降脂药物治疗后血脂管理并不达标。已有研究发现,前蛋白转化酶枯草杆菌蛋白酶/kexin9型(PCSK9)在血脂代谢中具有重要作用,而针对此靶点研发的PCSK9抑制剂投入临床后已积累了大量有效性与安全性方面的数据。本文主要针对PCSK9抑制剂的临床研究进行综述,为其在临床实践中的进一步应用提供参考依据。

To strengthen the management of dyslipidaemias in patients with atherosclerotic cardiovascular disease(ASCVD)is regarded as an important measure to delay the disease progression and improve the long-term prognosis.However,there are still a high proportion of domestic patients,whose lipids levels are not up to the standard after receiving conventional lipid lowering therapy,causing an unoptimistic form of lipids management of ASCVD patients in China.As researchers found the role of proprotein convertase subtilisin/kexin type 9(PCSK9)in lipid metabolism,targeted PCSK9 inhibitors have been put into clinical researches gradually and accumulated series evidence on efficacy and safety.Main literature referred to the clinical research and application progress of PCSK9 inhibitors were reviewed in present paper,to provide a reference for future clinical practice.